David M. Rodman

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

Michael Boyle, Scott C. Bell, Michael W. Konstan et al. · The Lancet Respiratory Medicine · 2014 · 442 citations

Pharmacy, Molecular Genetics, Pharmacotherapy +11

Repeated Adeno-Associated Virus Serotype 2 Aerosol-Mediated Cystic Fibrosis Transmembrane Regulator Gene Transfer to the Lungs of Patients With Cystic Fibrosis

Richard B. Moss, David M. Rodman, L. Terry Spencer et al. · CHEST Journal · 2004 · 388 citations

Life Sciences, Infectious Diseases, Molecular Biology +14

The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia

Karen A. Fagan, Brian Fouty, Robert Claude Tyler et al. · Journal of Clinical Investigation · 1999 · 307 citations · Full text

Life Sciences, Cardiology, Physiology +17

Pulmonary Hypertension in Transgenic Mice Expressing a Dominant-Negative BMPRII Gene in Smooth Muscle

James West, Karen Fagan, Wolfgang Steudel et al. · Circulation Research · 2004 · 263 citations

Life Sciences, Developmental Biology, Molecular Biology +16

Pulmonary Fibrosis and Chronic Lung Inflammation in ET-1 Transgenic Mice

Berthold Hocher, Anja Schwarz, Karen A. Fagan et al. · American Journal of Respiratory Cell and Molecular Biology · 2000 · 220 citations

Veterinary Medicine, Immunology, Pathobiology +16